Oncology

NICE issues new Technology Appraisals on brentuximab, gilteritinib, and entrectinib

September 2020

NICE has published four new Technology Appraisals (TAs): TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma TA642: Gilteritinib for treating relapsed […]

ASCO guideline on metastatic pancreatic cancer updated

September 2020

The American Society of Clinical Oncology (ASCO) have updated their guideline on metastatic pancreatic cancer, Metastatic Pancreatic Cancer: ASCO Guideline Update. The purpose of the […]

The impact of COVID-19 on specialised services

September 2020 | By Impacts of COVID-19 on specialised services interview panel

The COVID-19 emergency has been unprecedented in its impact upon the nation, economy, and health service. In anticipation of thousands of patients requiring ventilation, the […]

Histology-independent cancer drugs—navigating the uncertainties of innovative treatments

September 2020 | By Martin Bradley

Significant advances in cancer therapy have been made in recent decades. The elucidation of specific aspects of tumour biochemistry and genetics has led to an […]

NHS announces £160 million funding for COVID-friendly cancer treatments

September 2020

Sir Simon Stevens, NHS Chief Executive, has announced that the provision of COVID-friendly cancer treatments will be expanded through a £160 million initiative. The funding […]

New review explains the relationship between cancer and kidney disease

August 2020

A new review has been published that explains the relationship between cancer and kidney disease. Kidney disease can both lead to, and result from, cancer. […]

Articles